Mode of action | Product Candidate or Program | Indication | Discovery | Pre-clinical | Phase 1 | Phase 2 | Phase 3/ Pivotal |
Cancer metabolism Tumor starvation |
eryaspase /GRASPA® (asparaginase) |
Pancreatic Cancer 2L | |||||
Triple Negative Breast Cancer 1L | |||||||
Acute Lymphoblastic Leukemia 2L | |||||||
Pancreatic cancer 1L | |||||||
erymethionase (Methionine-γ-Lyase) | Solid tumors | ||||||
Immune modulation | Immuno-oncology Tolerance induction | TBD* | ![]() |
||||
Enzyme replacement | Therapeutic Enzymes | Metabolic diseases |
Arrow indicates most advanced study within an indication or program; more detail is provided in subsequent slides
* To be determined by SQZ Biotech